Market speculations and industry rumors regarding a potential transaction were conclusively resolved when GSK officially announced a definitive agreement to acquire Nuvalent for approximately $10.6 billion. This strategic multi-billion-dollar buyout successfully secured Nuvalent's advanced pipeline of near-approval non-small cell lung cancer therapies, significantly reinforcing GSK's long-term oncology commercialization and leadership footprint.